SMS biotech

The future of regenerative healing.

www.smsbiotech.com

Small Mobile Stem (SMS) Cells

SMS cells are found natively in the bloodstream.

Obtained from Adult human blood samples

- Just two blood vials from one donor will generate trillions of SMS cells that can be applied to many patients.

Extensively Safety Tested

- Both in-vitro and in-vivo testing in multiple animal species show no cellular toxicity or tumour generation.

Massive Regenerative Performance

- SMS cells stimulate regenerative cell growth and show rapid tissue healing in testing.

© 2025 All rights reserved | SMSbiotech

One Cell to Heal Them All

SMS cells are better in every way than current alternatives:

- Non-Immunogenic
- Anti-inflammatory
- Multi-targeting
- Small and fast
- Easy to administer

Supply

Ideal for mass-production, storage and distribution

Qualities

Small and stable with low risk of side effects

Cell Structure

Exceptionally resilient and robust

Harvesting

Simple procedure from an abundant source

Lifespan

Can grow for years while maintaining potency

Flexible

Able to be used in a wide variety of applications

© 2025 All rights reserved | SMSbiotech

How Much Better?

SMS Cells are so dramatically better that they maintain near 100% potency for 30 days at standard refrigeration temperatures. That's more than triple the lifespan of current mainstream cells with exponentially better viability.



Taking on COPD

Chronic obstructive pulmonary disease, or COPD, has 400M active patients and is the 3rd leading cause of death worldwide at 3M deaths yearly and is thought to be irreversible or uncurable...until now.

SMS cells do what no other treatment can.

Administer via NEBULIZER

We are the only technology able to achieve this as no other cells are hearty enough to survive.

Stimulates REGENERATION

SMS cells stimulate growth in lung cells, blood vessel formation, and can regenerate the air sacks.

Complete RECOVERY

In our animal studies we saw animal lungs make a complete recovery.

© 2025 All rights reserved | SMSbiotech

A Platform to Build On

Our platform is actively producing cell treatments in the areas of COPD and Orthopedics. These treatments are currently limited to use in research and ongoing clinical trials on paths to global commercialization.

Veterinary Applications

Canine & equine joint repair, wound healing under vet care

Phase 1 Clinical Trials

Phase 1 COPD therapy trial under FDA & Australian standards

Aesthetic & Wellness

Topical regenerative products in medical spas

Human Joint Therapy

Compassionate-use joint treatments under licensed institutions

Future project areas include:

- Neurologic
- Cardiovascular
- Organ Disease
- Oral & Dental
- Cancer Therapy
- Cell & Tissue Engineering
- Longevity
- and many more...

© 2025 All rights reserved | SMSbiotech

Intellectual Property

In cooperation with a leading IP firm, Knobbe Martens, SMSbiotech has filed 15 patents and has received 6.

Small Mobile Stem Cells (Sms) And Uses Thereof (US20190010448A1)

Stem Cell Compositions And Methods Of Repairing Tissue (WO2021183287)

Method and kit for vessel formation using SMS stem cell-produced ECM and substrates (WO2021071697A1)

Compositions And Methods For Using Small Mobile Stem Cells (US20200299649A1)

- 小型運動性幹細胞を使用した組成物および方法 (Japan JP2019513416A)
- Compositions And Methods For Using Small Mobile Stem Cells (UK)

Extracellular Matrix Protein Compositions And Methods For Treating Wounds (WO2020068432A1)

- 細胞外マトリックスタンパク質組成物および創傷の治療方法 (Japan)

In addition to patents, SMSbiotech owns TRADE SECRETS involving the biomanufacturing of the SMS cells and its quality control.

© 2025 All rights reserved | SMSbiotech

Our Future – Ramping Up Production

We are already producing SMS cells and currently have $8M worth of inventory. This year we began work on a new facility capable of scaling up production.

This new facility will allow us to:

More Efficiently Produce Cells

- Our new facility will allow us to greatly increase production of cells at much more efficient cost.

Capacity to Generate up to $25M/yr in Revenue

- We will utilize cells in clinical trials as well as anticipated growing demand for compassionate use applications.

Get Ahead of Increased Demand

- Global compassionate use will be an ongoing revenue source as will call for SMS cells to be used other clinical studies.

© 2025 All rights reserved | SMSbiotech

Current Roadmap

Clinical Trials

- Phase I - ongoing, expected to be completed in 2025
- Phase II – expected to begin Q1 ‘26 and complete in Q4 ‘26
- Phase III – expected to begin Q1 ‘27 and complete in Q4 ‘27

Journey So Far

- Animal safety studies – completed Q4 ‘23
- Product development – completed Q4 ‘23
- Compassionate Use application already filed in US/Internationally with focus on COPD patients

1 Phase I - 2025

2 Phase II - 2026

3 Phase III - 2027

© 2025 All rights reserved | SMSbiotech

Executive Leadership

Abdulkader Rahmo, PhD

Co-founder, President, Chief Scientific Officer

Bachelors in biochemistry from the Swiss Federal Institute of Technology in Zurich; Ph.D. in Biochemistry from the University of Southern California in Los Angeles. Associate professor, with +30 years of experience in basic and applied research; 12 years primarily focused on SMS cell discovery and development. Experienced in clinical laboratory medicine. Cofounded and lead several private and public entities including the National Commission for Biotechnology. Member of the Board of Directors at California Medical Innovations Institute.

Ghassan Kassab, PhD

Board Member

Founder/President/CSO of California Medical Innovations Institute in San Diego, Founder of 3DT Holdings (incubator/accelerator of medical devices), and Founder of Acculab Lifesciences. Former professor (in Biomedical Engineering, Surgery, Cellular & Integrative Physiology) at Purdue University. Published over 700 publications and has over 250 issued or pending patents. He sold a major technology and sold four exclusive licenses to the major medical device industry. Board of director member for SMSbiotech.

© 2025 All rights reserved | SMSbiotech

Leadership Team

Harry Friedman

CFO, Board of Directors Member at SMSbiotech

Seasoned Businessman, Investor, and Consultant Experienced Board Member. Self- financed a high-growth technology company that successfully sold, 20-plus years later, to a large conglomerate. Started and participated in growing and selling several technology companies. Was a long-time member of Tech Coast Angels.

Jason Kirkness, Ph.D.

Global Clinical Program Lead – Respiratory at SMSbiotech

A globally recognized medical science executive and pulmonary physiologist with extensive expertise in clinical research, medical device development, and innovation in respiratory medicine. He serves as Chairman of Drug Device Discovery and Development at the American Thoracic Society (ATS), Board of Directors for the ATS and is a member of the RIS Organizing Committee. Previously, he held senior roles at 4DMedical and Fisher & Paykel Healthcare. Has led over 100 clinical trials, secured significant funding from NIH and NHMRC, and authored over 50 high-impact publications. He is an Adjunct Associate Professor at the University of Miami and a former faculty member at Johns Hopkins.

Prof. Peter Wagner, MD

Board of Advisors Member at SMSbiotech

Emeritus Prof. at UCSD, leader in Respiratory Physiology, served as the Pres. of the American Thoracic Society, Pres. of the American Physiological Society, and Division Chief of both Physiology and Pulmonary Critical Care at UCSD School of Medicine, and as both member and chair of National Institutes of Health study sections.

Gary Sieck, Ph.D.

Advisor at SMSbiotech

Prof. of Physiology at Mayo Clinic School of Medicine and Science. Studies focus on cell signaling mechanisms that underlie muscle performance, with a focus on regenerative processes that can improve acute and chronic disease conditions. He has published over 380 peer-reviewed papers and received multiple NIH grants over 37+ years.

Roger Schechter, MD

Clinical Research Director at SMSbiotech

FACEP, FCCWS, UHM-ABEM, Medical Director for Wound Management at Palomar Health San Diego, Chief Medical Officer at Synergy Wound Technology, trained in Emergency Medicine, practices full time as a Wound Care and Hyperbaric Medicine Physician, a national level speaker on wound care, advanced wound care modalities, and non-invasive vascular testing.

David Schmitt, DVM

Veterinary Clinical Research Director at SMSbiotech

A Life Member of the Iowa Veterinary Medical Association (IVMA) with +40 years of service, retired as the Iowa State Veterinarian in 2019 after a distinguished career in both private practice and public service. Served as the State Veterinarian for IDALS, was a key figure in veterinary legislation, has received numerous honors, including Veterinarian of the Year by the IVMA. Served as President of the United States Animal Health Association.

Joe Kiani

Board of Directors Member at SMSbiotech

Cofounder of Masimo Corporation; Employing more than 4,250 people worldwide. Kiani and Masimo have more than 595 issued and 310 pending patents worldwide.

Prof. James Sherley, MD

Board of Advisors Member at SMSbiotech

Former Associate professor at MIT (nine years), founder and former director of the Adult Stem Cell Technology Center at the Boston Biomedical Research Institute (5yrs); currently SMSbiotech board of advisor member, founder, and Director of Asymmetrex, LLC, Adjunct Associate Professor, Hematology-Oncology Department, Rhode Island Hospital Brown University.

© 2025 All rights reserved | SMSbiotech

Investor Exit Strategies

We are confident that there will be many exit opportunities along the journey of SMSbiotech. One possibility is acquisition, as big players often rely on the innovation of smaller companies. See the examples provided below.

Rodeo Therapeutics

Tissue Generation & IPF

Pre-Clinical

Acquired for $700M+ by Amgen in 2021

Kadmon Corporation

Graft Versus Host Disease

Phase II Clinical

Acquired for $1.9B by Sanofi in 2021

Forma Therapeutics

Sickle Cell Disease

Phase II, III Clinical

Acquired for $1B by Novo Nordisk in 2022

Additionally, we are exploring the following options:

- IPO
- Developing and segmenting solutions by their therapy application
- Licensing for those individual applications

© 2025 All rights reserved | SMSbiotech

Investment Offer Details

Now, there's a limited-time opportunity for you to join us and help change the meaning of healing.

Share Price	$28.13	Minimum Investment	$10,000
Round Size	$15.75M	Eligibility	Accredited Investors

Qualified Investments Get

Up to **20%** volume based share price discounts available

+

Limited access to **100%** warrant coverage up to the first $5M raised

SMS biotech

Take the next step.

Book your

one on one call!